← feed

Is NCT00833963 results overdue?

Yes — results are overdue. Primary completion was 2017-04-13; the FDAAA-801 reporting deadline (2018-04-13) passed 2991 days ago and no results are posted on ClinicalTrials.gov.

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

NCT IDNCT00833963 ↗
SponsorGenentech, Inc. (INDUSTRY)
Phase
StatusCOMPLETED
Primary completion2017-04-13 (ACTUAL)
Reporting deadline2018-04-13 (completion + 365d)
Days overdue2991
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 4aca71f6a22c9a20… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT00833963. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →